secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001104659-22-117219
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccitech Q3 net income $8.2M; cash $200.1M; first patient dosed in VTP-300 Phase 2b
--------------------------------------------------------------------------------

- Net income of $8.2M ($0.22 per share) vs $15.7M in Q2 2022; revenue fell to $6.2M from $17.1M as no milestones.
- Cash and equivalents $200.1M as of Sep 30, 2022, down from $214.1M at Dec 31, 2021; cash runway into Q1 2025.
- Dosed first patient in Phase 2b trial of VTP-300 for HBV; Phase 1b/2a data showed HBsAg reduction in CHB patients.
- Promoted Gemma Brown to CFO effective Sep 20, 2022.
- Expects to open Phase 1/2 trial for prostate cancer candidate VTP-850 in Q4 2022; IND submissions for SNAPvax programs in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465922117219/0001104659-22-117219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465922117219/tm2230034d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer